Rheumatoid Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2022
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or exhibit an inadequate response, the U.S. market is crowded with efficacious biologics and targeted oral therapies, including blockbuster TNF-alpha inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) as well as non-TNF-alpha inhibitors, such as BMS’s Orencia and Roche’s Actemra, and the oral JAK inhibitors, Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). Indeed, the FDA approval of Rinvoq had led to increased competition within the JAK class and among the non-TNF biologics. However, the recent extension of the FDA’s safety warnings to the entire JAK class will likely impact the overall use of these drugs, leading to increased use of other targeted agents.
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed RA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed RA patients?
- How have non-TNF biologics and JAK inhibitors been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of RA patients receive drug therapy within three years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?
- What percentage of RA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Amgen, Biogen, BMS, Eli Lilly, Janssen, Pfizer, Roche, Regeneron, Sanofi, UCB.
Key drugs: Actemra, biosimilar infliximab, Cimzia, Enbrel, Humira, Kevzara, Olumiant, Orencia, Remicade, Rinvoq, Rituxan, Simponi, Simponi Aria, Xeljanz.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
